Concurrent chemoradiotherapy is an established treatment modality for several solid malignancies, but its role in breast cancer remains under active investigation. Recent clinical trial data evaluated preoperative hypofractionated chemoradiotherapy in non-metastatic HER2-positive and triple-negative breast cancer subtypes. Consequently, this neoadjuvant approach demonstrated encouraging local disease control, exceptional long-term survival, and acceptable toxicity. Therefore, clinicians are re-evaluating traditional timing sequence strategies for radiation delivery in aggressive tumor phenotypes.

Preoperative Hypofractionated Chemoradiotherapy Protocol Details

In this prospective single-center study, researchers evaluated 62 patients with non-metastatic HER2-positive or triple-negative breast cancer treated between 2018 and 2022. The median patient age was 53 years, representing a population with aggressive biological tumor profiles. Subtype distribution included 28 triple-negative cases (45%) and 34 HER2-positive cases (55%). Overall, 60 out of 62 patients completed the preoperative concurrent treatment protocol as planned.

The treatment protocol combined hypofractionated radiation therapy with subtype-specific systemic agent administration. Radiation delivered 40.5 Gy across 15 fractions to the whole breast, alongside a simultaneous integrated boost reaching 54 Gy targeting the primary macroscopic tumor mass. Clinicians utilized 18-FDG-PET-CT imaging guidance to define precise target volumes for radiation delivery. Systemic therapy ran concurrently with radiation, offering targeted biological activity or aggressive cytotoxic agents tailored to tumor receptor status. Following completion of the preoperative phase, patients underwent definitive surgical intervention 4 to 6 weeks later. This structured timeline allowed adequate tissue recovery, promoted primary tumor downstaging, and minimized surgical site complications. Furthermore, the integration of advanced imaging ensured optimal radiation target accuracy while limiting exposure to surrounding thoracic tissues.

Pathologic Response Rates in TNBC and HER2-Positive Subtypes

Pathological response serves as a critical surrogate marker for long-term clinical prognosis in early breast cancer management. Primary study endpoints specifically evaluated pathological complete response (pCR), defined as Miller-Payne Grade 5. Overall, the preoperative concurrent chemoradiotherapy protocol achieved an impressive pCR rate of 60% across the complete cohort. Subgroup analyses revealed distinct response patterns based on molecular tumor profiles. Specifically, patients with triple-negative breast cancer achieved a 70% pCR rate, whereas patients with HER2-positive disease achieved a 52% pCR rate.

Achieving complete tumor elimination prior to surgical resection provides substantial clinical value in aggressive breast cancer phenotypes. Furthermore, breast-conserving surgery was successfully achieved in 68% of enrolled patients, demonstrating effective primary tumor downstaging. Although pCR typically correlates with survival outcomes in neoadjuvant chemotherapy trials, statistical analysis in this specific pilot study found no significant correlation between pCR status and overall survival. Nevertheless, the high proportion of patients achieving complete pathological regression underscores the profound local antitumor activity of concurrent radiation and systemic treatment. Consequently, preoperative delivery may overcome inherent treatment resistance in high-risk phenotypes.

Long-Term Survival Metrics and Locoregional Recurrence

Evaluating long-term oncological outcomes is essential when introducing novel sequence modifications into established treatment algorithms. During a median follow-up period of 60.7 months, the long-term survival metrics demonstrated remarkably strong disease control. The 5-year locoregional recurrence-free survival reached 100%, indicating complete absence of local or regional treatment failures within the treated surgical field. Simultaneously, 5-year disease-free survival, distant metastasis-free survival, and overall survival all reached 95%.

These long-term findings highlight the sustained efficacy of the preoperative hypofractionated chemoradiotherapy regimen over extended clinical follow-up. Throughout the five-year evaluation window, only three patients experienced distant disease recurrence, and only one death was directly attributed to breast cancer progression. Additionally, two patients (3%) developed independent contralateral primary breast cancers during follow-up. Medical teams treated both contralateral cases using standard therapeutic protocols, and both patients remain completely disease-free to date. Therefore, combining concurrent radiation with systemic therapy before surgery provides durable locoregional control while effectively preventing distant metastatic dissemination in high-risk patient populations. Consequently, these outcomes highlight the therapeutic value of preoperative radiotherapeutic paradigms.

Safety Profile and Cardiac Toxicity Considerations

Safety and tolerability remain central concerns when administering concurrent chemoradiotherapy, given the potential for additive toxicities. Fortunately, no grade 3 or higher late toxicities were observed throughout the extended follow-up period. Regarding acute adverse events, hematological toxicity presented primarily as transient cytopenias. Specifically, Grade 2 cytopenia occurred in 43% of patients, Grade 3 cytopenia in 26%, and Grade 4 cytopenia in 13.7%. Two patients died prior to surgery; one mortality resulted from chemotherapy-related sepsis, whereas the second death occurred due to causes completely unrelated to treatment.

Because concurrent HER2-targeted therapy and left-sided radiation carry potential cardiotoxicity risks, cardiac parameters received rigorous monitoring. Asymptomatic, transient declines in left ventricular ejection fraction occurred in 7% of HER2-positive patients. Importantly, all instances of cardiac dysfunction resolved completely during routine clinical follow-up without persistent functional impairment. Thus, the overall safety profile of this hypofractionated schedule appears manageable for carefully selected patients. Careful monitoring of acute hematological events remains mandatory to prevent severe systemic complications during preoperative care. Nevertheless, low rates of severe late toxicity reinforce treatment feasibility.

Surgical Feasibility, Reconstruction, and Clinical Implications

Surgical feasibility and cosmetic preservation represent essential evaluation metrics when integrating preoperative radiation therapy into primary breast cancer management. In this study, 68% of patients underwent successful breast-conserving surgery, with cosmetic results rated as excellent or good in all breast-conserving cases. Meanwhile, 19 patients (32%) required total mastectomy to achieve clear surgical margins. Among the mastectomy cohort, 11 patients underwent breast reconstruction.

Surgical outcome analysis revealed a statistically significant advantage regarding reconstruction technique selection. Specifically, reconstruction outcomes significantly favored autologous tissue reconstruction over heterologous implant-based techniques (p = 0.003). Autologous tissues appeared more resilient following preoperative radiation, demonstrating lower complication rates and superior aesthetic integration. Therefore, clinicians planning reconstruction after preoperative chemoradiotherapy should prioritize autologous tissue options.

Overall, these five-year findings demonstrate that preoperative hypofractionated chemoradiotherapy is highly feasible. Preoperative delivery capitalizes on superior tissue vascularization in untreated intact tumors, optimizing radiobiological cell destruction. However, because this pilot trial included 62 patients from a single institution, confirmation through larger prospective randomized controlled trials is strictly warranted to validate these survival benefits.

Frequently Asked Questions

What are the primary benefits of preoperative hypofractionated chemoradiotherapy in breast cancer?

Preoperative hypofractionated chemoradiotherapy delivers concentrated radiation directly to intact, well-oxygenated tumor tissue before surgery. This approach achieves high pathological complete response rates, promotes tumor downstaging, and increases the feasibility of breast-conserving surgery. Additionally, concurrent delivery optimizes synergistic cell killing and reduces overall treatment duration compared to standard post-surgical schedules. Consequently, patients benefit from excellent long-term locoregional control and high overall survival rates without significant late radiation toxicities.

How did cardiac safety outcomes compare during concurrent treatment in HER2-positive patients?

In HER2-positive breast cancer patients receiving concurrent targeted therapy and radiation, transient asymptomatic declines in left ventricular ejection fraction occurred in 7% of cases. Crucially, all cardiac events completely resolved during regular clinical follow-up without permanent structural or functional heart damage. Careful monitoring of cardiac function remains essential during treatment, but these findings confirm that hypofractionated radiation can be safely combined with subtype-specific biological agents under experienced multidisciplinary supervision.

Why did autologous reconstruction show better outcomes than heterologous techniques after preoperative radiotherapy?

Autologous tissue reconstruction demonstrated significantly superior outcomes compared to heterologous implant techniques (p = 0.003). Preoperative radiation alters host tissue compliance and vascularization, which can increase complication rates around artificial synthetic implants. In contrast, autologous tissue flaps bring healthy, non-irradiated vascular supply into the surgical field, facilitating better wound healing, lower capsular contracture risks, and superior long-term aesthetic integration. Consequently, autologous options are highly preferred when reconstruction is required following preoperative chemoradiotherapy.

Disclaimer: This content is for informational and educational purposes only, and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should rely on their clinical judgment and refer to the latest local and national guidelines for clinical practice.

References

1. Ciérvide R et al. Long-term results of preoperative hypofractionated chemoradiotherapy for high-risk HER2-positive and triple-negative breast cancer subtypes. Clin Transl Oncol. 2026 Aug 08. doi: 10.1007/s12094-026-04527-x. PMID: 42570990.


2. Montero A, Ciérvide R. Preoperative Radio(Chemo)Therapy in Breast Cancer: Time to Switch the Perspective? Curr Oncol. 2022 Dec 12;29(12):9767-9787. doi: 10.3390/curroncol29120768. PMID: 36547182.